Is Antimicrobial Photodynamic Therapy Effective as an Adjunct to Scaling and Root Planing in Patients with Chronic Periodontitis? A Systematic Review

Betsy Joseph 1, Presanthila Janam 2, Subhash Narayanan 3 and Sukumaran Anil 4,*

1 Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha 62521, Saudi Arabia; bjoseph@kku.edu.sa
2 Department of Periodontics, PMS College of Dental Sciences, Trivandrum, Kerala 695028, India; ksuco@gmai.com
3 Sascan Meditech Private Limited, Centre for Innovation in Medical Electronics, BMS College of Engineering, Bangalore 560019, India; drsubashnarayanan@gmail.com
4 Department of Periodontics, Saveetha Dental College and Hospitals, Saveetha University, Poonamallee High Road, Chennai 600077, India
* Correspondence: drsanil@gmail.com; Tel.: +91-94967-49734

Academic Editor: Jürg Bähler
Received: 12 October 2017; Accepted: 20 November 2017; Published: 24 November 2017

Abstract: The aim of this systematic review was to investigate whether antimicrobial photodynamic therapy (aPDT) as either a primary mode of treatment or an adjunct to non-surgical treatment was more effective than scaling and root planing (SRP) alone in treating chronic periodontitis in terms of clinical attachment level (CAL) gain and probing depth (PD) reduction. The focused question was developed using the Patient, Intervention, Comparison, and Outcome (PICO) format, and two authors independently searched the Medline, EMBASE, Cochrane Library, Web of Science, Google Scholar, and Scopus databases for relevant studies from January 2008 to December 2016. Twenty studies included in this systematic review were randomized clinical trials (RCTs) or quasi-RCTs of aPDT compared to placebo, no intervention, or non-surgical treatment in an adult population. Basic study characteristics, photosensitizing agents and wavelengths used in aPDT, frequency of aPDT application, effect of aPDT on clinical parameters, antimicrobial effect of aPDT in chronic periodontitis, effect of immunological parameters following aPDT and patient-based outcome measures were collected from the studies. Although there was a wide range of heterogeneity in the included studies, they all indicated that aPDT has the potential to be an effective adjunct in the treatment of chronic periodontitis. Long-term, multicenter studies with larger sample sizes are needed before aPDT can be recommended as an effective treatment modality.

Keywords: photodynamic therapy; bacterial biofilm; chronic periodontitis; photochemotherapy; systematic review

1. Introduction

The ultimate goal of periodontal therapy is to eliminate supragingival and subgingival plaque and arrest the progression of periodontal disease. Scaling and root planing (SRP) are considered as the gold standard for the treatment of chronic periodontitis. Although many studies have shown significant improvements following SRP, complete elimination of subgingival periodontal pathogens and irritants is not always possible [1,2]. Residual pockets during SRP present similar challenges and additional therapeutic approaches to achieving periodontal health are required. To improve the results of mechanical debridement, antibiotics are widely used [3,4]. Limitations of drug resistance...
associated with the use of local and systemic medications have led to the popularity of antimicrobial photodynamic therapy (aPDT) in the management of chronic periodontitis. aPDT was introduced in 1904 as the light-induced inactivation of cells, microorganisms or molecules. This treatment modality is based on the principle that a photoactivatable substance, called a photosensitizer, is activated by the light of a particular wavelength. The transfer of energy causes the formation of free radicals of singlet oxygen, which exert destructive action on bacteria and their products [5,6].

Even though the effects of photodynamic action have been known for a long time, interest in its practical use has increased only in the last few years. Because several studies had shown that killing both Gram-positive and Gram-negative bacteria is possible, Wilson’s group in London investigated different aspects of the application of aPDT in dentistry in vitro and in vivo [7–9]. In the presence of various types of photosensitizers, such as toluidine blue O and methylene blue, several periodontal pathogens are found to be susceptible to red lasers, which points to the fact that aPDT could be could be advantageous in periodontal therapy [10]. However, randomized controlled trials and systematic reviews have shown contrasting results regarding the efficacy of aPDT in chronic periodontitis [10–16]. Hence, the objective of the systematic review was to determine the effectiveness of aPDT as a primary mode or as an adjunct to non-surgical periodontal therapy.

2. Methodology

2.1. Search Strategy

The search strategy was based on the question “Is aPDT as either a primary mode of treatment or an adjunct to non-surgical treatment more effective than SRP alone in chronic periodontitis in terms of clinical attachment level (CAL) gain and probing depth (PD) reduction?”. This focused question was developed using the Patient, Intervention, Comparison, and Outcome (PICO) format [17]. Two authors independently searched the Medline, EMBASE, Cochrane Library, Web of Science, Google Scholar, and Scopus databases from January 2008 to December 2016 for relevant studies. The following terms in various combinations were used: bacteria, diode laser, lethal photosensitization, photodynamic inactivation, photodynamic antimicrobial chemotherapy, photodynamic therapy, and periodontitis.

2.2. Eligibility and Information Sources

The 20 studies included in this systematic review were randomized clinical trials (RCTs) or quasi-RCTs of aPDT compared to placebo, no intervention, or non-surgical treatment in an adult population (Figure 1). In all studies, aPDT was either a primary mode of therapy or an adjunct to other non-surgical treatments, with CAL and/or PD as the primary outcome measures. Studies of aPDT used for the treatment of periodontitis at any dosage or duration were included. Eligible control interventions that were considered for this systematic review were placebo, no treatment, or non-surgical periodontal treatment (independent of or as adjunct therapy). Letters to the editor, short commentaries, and review articles were excluded.

2.3. Study Selection and Data Collection

To minimize the potential for reviewer bias, two blinded reviewers independently screened all titles and abstracts identified through electronic and manual searches. Disagreements regarding the inclusion or exclusion of studies were resolved by a discussion between the reviewers. Two reviewers used an extraction form to categorize the included articles in terms of patient demographic characteristics, presence of smokers, laser settings, and reported outcomes measures. The quality of the studies included in the systematic review was determined separately by two independent reviewers.
Figure 1. Decision tree showing the selection of articles included in the review. aPDT: antimicrobial photodynamic therapy; PDT: photodynamic therapy.

3. Results

3.1. Study Characteristics

The mean age of patients in the studies included in this review ranged from 39.6 years to 62.8 years. Studies that recruited patients with chronic periodontitis were included in this review. The characteristics of the included studies are shown in Table 1. Criteria of chronic periodontitis [12], severe periodontitis [18], pocket depth ≥ 5 mm [19–22], untreated periodontal pockets [12], pocket depth between 4 and 6 mm [23,24], pocket depth between 5 and 9 mm [25], and residual pockets during supportive periodontal therapy [13,26–30] were used. The presence of Fusobacterium nucleatum in localized chronic periodontitis was an inclusion criterion in one study [31]. Most of the studies included either single-rooted teeth or both single- and multi-rooted teeth, while two studies reported the effects of aPDT only in multi-rooted teeth [19,32]. Most of the remaining studies evaluated aPDT as both an adjunct to SRP in the management of chronic periodontitis and a monotherapy [24,26,27,30].
### Table 1. Studies on aPDT in chronic periodontitis with clinical attachment level (CAL) or probing depth (PD) as the primary outcome measures.

| Author          | Country | Sample Size (Male/Female) and Mean Age | Study design; Power of Study; Case Allotment | Outcome Measured                                                        | Treatment Arms                                      | Conclusion                                                                 |
|-----------------|---------|----------------------------------------|---------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------------------|
| Kolbe et al.    | Brazil  | 22 (10/12) 48.52 y                     | Split-mouth                                 | Clinical, Microbiology (polymerase chain reaction (PCR)); Pain perception (Visual Analogue Scale (VAS)) | Scaling and Root Planing (SRP) aPDT Photosensitizer | All therapies promoted similar improvements in clinical parameters. The aPDT protocol presented inferior frequency of *Porphyromonas gingivalis* at three months when compared with the other therapies. aPDT as an exclusive therapy may be considered a non-invasive alternative for treating residual pockets and offers advantages in the modulation of cytokines. |
| Carvalho et al. | Brazil  | 34 (21/13) 48 y                        | Parallel                                    | Pocket probing depth (PPD), CAL, bleeding on probing (BoP) and plaque index (PI) | SRP aPDT                                           | Both treatments resulted in significant clinical improvement in patients with residual periodontal pockets. We did not find any additional significant benefit of PDT in terms of PPD, CAL, BoP, or pathogen level reduction. |
| Betsy et al.    | India   | 90 (39/51) 39.6 y                      | Parallel                                    | Clinical and halitosis as perceived by patient                         | SRP SRP + aPDT                                     | PD improved after three months and halitosis after one month. Statistically significant improvements in the gingival index and gingival bleeding index were observed for the test group after two weeks and one month of aPDT, respectively. aPDT is a beneficial adjunct to SRP in the non-surgical treatment and management of chronic periodontitis in the short term. |
| Luchesi et al.  | Brazil  | 37 50.5 y                              | Parallel                                    | Clinical, Microbiology (PCR), Immunology (granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN), Interleukin (IL)-6 and Interleukin-8 levels) | SRP aPDT SRP + non-activated light (only PS)       | Clinical parameters improved after both therapies. Did not promote clinical benefits for class II furcations; however, there were advantages in terms of the local levels of cytokines and periodontopathogens reduction. |
| Dilsiz et al.   | Turkey  | 24 (10/14) 40.7 y                      | Split-mouth                                 | SRP SRP + aPDT SRP + KTP                                              |                                                    | Improvement in PD and CAL gain following treatment. Additional use of potassium titanyl phosphate (KTP) laser was found to be better in improving clinical parameters than conventional periodontal therapy of deeper pockets. |
| Alwaeli et al.  | Malaysia| 21 (7/14) 40.9 y                       | Split-mouth                                 | SRP SRP + aPDT                                                       |                                                    | Significant improvement in all evaluated clinical parameters for at least one year. There were significantly greater reductions and gains for SRP + aPDT than for SRP at all three-time points. aPDT as an adjunctive therapy to SRP represents a promising therapeutic concept for persistent periodontitis. |
| Campanile et al.| Switzerland | 27 (14/13) 62.8 y                     | Parallel Smokers included 80% (PD) Computer-generated | Clinical, Microbiology (PCR); Pain perception (VAS); Immunology (C-reactive protein, Serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin) | aPDT twice in one week aPDT once Sham without active light | Significant PD and BoP reduction after three months when aPDT was administered twice a week. C-reactive protein was significantly lower only when the laser had been activated twice. |
| Author            | Country | Sample Size (Male/Female) and Mean Age | Study design; Power of Study; Case Allotment | Outcome Measured | Treatment Arms | Conclusion |
|-------------------|---------|----------------------------------------|---------------------------------------------|------------------|----------------|-------------|
| Bassir et al. [24] | USA     | 16 (8/8) 50.3 y                        | Split-mouth 80% (CAL) Computer-generated     | Clinical         | LED PS aPDT SRP | No additional benefit was noticed with administration of photoactivated disinfection (PAD) using LED in patients with moderate to severe chronic periodontitis. |
| Campos et al. [34] | Brazil  | 15 (8/7) 48.1 y                        | Split-mouth 80% (PD) Computer-generated      | Clinical         | SRP + aPDT     | aPDT as an adjunctive to mechanical debridement demonstrated additional clinical benefits for residual pockets in single-rooted teeth and may be an alternative therapeutic strategy in supportive periodontal maintenance. |
| Balata et al. [18] | Brazil  | 22 (8/14) 43.18 y                      | Split-mouth 80% (CAL) Coin toss              | Clinical         | SRP + aPDT     | Both approaches resulted in significant clinical improvement in the treatment of severe chronic periodontitis. aPDT did not provide any additional benefit. |
| Barekdar et al. [21]| Germany | 22 (12/10) 59.3 y                      | Split-mouth                                   | Clinical         | SRP + aPDT     | A greater reduction of the PD was achieved by a combination of SRP/aPDT; therefore, aPDT is suitable as an adjuvant therapy. |
| Giannopoulou et al. [28] | Switzerland | 32 (23/9) 52 y                      | Split-mouth Smokers included 80% (PD) Computer-generated | Clinical, Immunology (IL-17, basic fibroblast growth factor, granulocyte-macrophage colony-stimulating factor (GCSF), macrophage inflammatory protein (MIP)) | SRP Diode laser aPDT | No significant differences were observed among the three treatment modalities at any time point for any biochemical parameter or enhanced expression of inflammatory mediators. |
| Cappuyns et al. [29] | Switzerland | 32 (23/9) 52 y                      | Split-mouth Smokers included 80% (PD) Computer-generated | Clinical, Microbiology (RNA probes); Pain perception (VAS) | SRP Diode laser aPDT | At the end of six months, statistically significant PD and BoP reductions were recorded. Frequencies of three periodontal pathogens were significantly lower in groups with aPDT and SRP-treated than in diode soft laser-treated quadrants after 14 days. However, the same was not noticed at the end of two and six months. aPDT resulted in a reduction in the number of pockets after six months. |
| Lui et al. [22]    | Hong Kong | 24 (10/14) 50 y                       | Split-mouth                                   | Clinical, Immunology (IL-1b levels in gingival crevicular fluid) | SRP + one course of low level laser therapy (LLT) and aPDT within 5 days | The test teeth achieved greater reductions in the percentage of sites with bleeding on probing and in mean probing depth at one month compared with the control teeth and also greater reduction of interleukin (IL)-1b levels in gingival crevicular fluid at 1 week than did the control sites. No significant differences in periodontal parameters were found between the test and control teeth at three months. |
| Author | Country | Sample Size (Male/Female) and Mean Age | Study design; Power of Study; Case Allotment | Outcome Measured | Treatment Arms | Conclusion |
|--------|---------|---------------------------------------|---------------------------------------------|-----------------|---------------|------------|
| Theodoro et al. [25] | Brazil | 33 (12/21) 43.12 y | Split-mouth 81% (CAL) Computer-generated | Clinical, Microbiology (PCR) | SRP SRP + Toluidine Blue O (TBO) SRP + aPDT | All treatment groups showed an improvement in all clinical parameters and a significant reduction in the proportion of sites positive for periodontopathogens at 60, 90, and 180 days compared to baseline. None of the periodontal parameters showed a significant difference among the groups. At 180 days, aPDT treatment led to a significant reduction in the percentage of sites positive for all bacteria compared to SRP alone. |
| Sigush et al. [31] | Germany | 24 (7/17) 42.7 y | Parallel Drawing lots | Clinical, Microbiology (PCR) | SRP + PS SRP + aPDT | Significant reductions in reddening, BoP, and mean PD and CAL were observed during the observation period and with respect to controls. Appropriate to reduce periodontal inflammation and to successfully treat infection with *Fusobacterium nucleatum*. |
| Ruhling et al. [30] | Germany | 60 48 y | Parallel 80% (PD) Computer-generated | | SRP aPDT | aPDT was not found to be better than routine mechanical debridement in the management of persistent pockets, but still maybe considered a valuable therapeutic option. |
| Christodoulides et al. [12] | Germany | 24 (13/11) 45 y | Parallel 80% (PD) Coin toss | SRP SRP + aPDT | | Additional application of a single episode of aPDT to SRP failed to result in an additional improvement in terms of PD reduction and CAL gain, but resulted in a significantly higher reduction in bleeding scores compared to SRP alone. |
| Braun et al. [11] | Germany | 20 (9/11) 46.6 y | Split-mouth | | SRP SRP + aPDT | Improvement in clinical parameters with the use of adjunctive aPDT as compared to subgingival debridement. |
| Chondros et al. [13] | Germany | 24 (10/14) 49.3 y | Parallel 80% (PD) Coin toss | Clinical, Microbiology (PCR) | SRP SRP + aPDT | Additional application of a single episode of aPDT to SRP failed to result in additional improvement. Significantly higher reduction of bleeding scores in test group. At three months and six months, a statistically significantly higher improvement of BoP was found in the test group. At three months after therapy, the microbiological analysis showed a statistically significant reduction of *F. nucleatum* and *Eubacterium nodatum* in the test group. |
3.2. Study Design

The included studies were RCTs published between 2008 and 2015. Of the 20 studies included, six were parallel two-arm [12,13,19,23,30,31], one was parallel three-arm [27], one was a split-mouth four-arm [24], five were split-mouth three-arm [20,25,26,28,29], and six were split-mouth two-arm studies [11,18,21,22,32,34]. In vitro studies, in vivo studies with animals, and clinical reports were excluded. In split-mouth RCTs, each subject is its own control, and most of the variability of outcome among patients is removed from the intervention effect estimate. Bias may be induced [35] due to the “spilling” of the effects of one therapy from one site to another. When evaluating the results of aPDT in split-mouth studies, the paired nature of the data must be taken into account [36]. Because every subject receives each intervention, the split-mouth design may be better suited to studies that determine patient preferences.

3.3. Sample Size and Calculation

The sample sizes ranged from 15 to 90, with all studies but four having more female participants than males [12,21,27,28]. Of the 29 studies, 13 reported on the calculation of sample size with the power of the study set at or above 80% (81–86). Among these, nine studies reported that sample size was calculated based on probing depth, while five used CAL as the primary outcome. Significant changes reported in the studies must be interpreted with caution because to detect even a moderate change, at least 40 patients may be needed in one arm of the treatment. Generally, 20% is added to compensate for any drop-outs. The sample size is calculated as the number of patients needed for one arm, but few studies adhered to that. The lack of sample size calculation and reported methods of randomization were the main methodological issues noted. The reasons for drop-outs were also not specified in most of the studies.

3.4. Blinding

Blinding is done in order to decrease or hide the information regarding the type of intervention given to a particular participant so that outcomes and assessments of outcomes are unaffected. In this review, eight studies were double-blinded, eight were single-blinded, and four did not mention the type of blinding. The examiner and biostatistician were blinded in these trials. Details are provided in Table 2.

Table 2. The sample size and method used to derive samples in the selected studies.

| Author(s) | Country | Sample Size (Male/Female) | Power of the Study (%) | Type of Randomization | Type of Blinding | Case Allotment | Whether Intention-to-Treat (ITT) Analysis Done |
|-----------|---------|---------------------------|------------------------|-----------------------|-----------------|---------------|---------------------------------------------|
| Kolbe et al. [26] | Brazil | 22 (10/12) | 83% (CAL) | Not mentioned | Double-blinded | Computer-generated | Yes |
| Carvalho et al. [33] | Brazil | 34 (21/13) | 90% (CAL) | Block randomization (size = 4) | Double-blinded | Computer-generated | Yes |
| Betsy et al. [23] | India | 90 (39/51) | 80% (PD) | Block randomization (size = 4) | Double-blinded | Tippet’s 2-digit number table | Yes |
| Luchesi et al. [19] | Brazil | 37 | 86% (CAL) | Not mentioned | Double-blinded | Computer-generated | Yes |
| Dilisz et al. [20] | Turkey | 24 (10/14) | Not given | Not mentioned | Double-blinded | Computer-generated | Yes |
| Alwaed et al. [32] | Malaysia | 21 (7/14) | Not given | Not mentioned | Double-blinded | Computer-generated | No |
| Campanile et al. [27] | Switzerland | 27 (14/13) | 80% (PD) | Not mentioned | Single-blinded | Computer-generated | No |
| Bassir et al. [24] | USA | 16 (8/8) | 80% (PD) | Block randomization (size = 1) | Double-blinded | Computer-generated | Not mentioned |
| Campos et al. [34] | Brazil | 15 | 80% (PD) | Not mentioned | Double-blinded | Computer-generated | Not mentioned |
Table 2. Cont.

| Author                    | Country   | Sample Size (Male/Female) | Power of the Study | Type of Randomization | Type of Blinding | Case Allotment          | Whether Intention-to-Treat (ITT) Analysis Done |
|---------------------------|-----------|---------------------------|--------------------|-----------------------|------------------|------------------------|-----------------------------------------------|
| Balata et al. [18]        | Brazil    | 22 (8/14)                 | 80% (CAL)          | Not mentioned         | Not given        | Coin toss              | Yes                                           |
| Banakdar et al. [21]      | Germany   | 22 (12/10)                | Not mentioned      | Not mentioned         | Single-blinded   | Not mentioned          | Yes                                           |
| Giannopoulou et al. [28]  | Switzerland | 32 (23/9)                 | 80% (PD)           | Not mentioned         | Not mentioned    | Computer-generated     | No                                            |
| Cappuyns et al. [29]      | Switzerland | 32 (23/9)                 | 80% (PD)           | Not mentioned         | Single-blinded   | Computer-generated     | No                                            |
| Lui et al. [22]           | Hong Kong | 24 (10/14)                | Not mentioned      | Not mentioned         | Single-blinded   | Not mentioned          | Yes                                           |
| Theodoro et al. [25]      | Brazil    | 33 (12/21)                | 81% (CAL)          | Not mentioned         | Single-blinded   | Computer-generated     | Yes                                           |
| Sigush et al. [31]        | Germany   | 24 (7/17)                 | Not mentioned      | Not given             | Drawing lots     | Not mentioned          |                                               |
| Ruhing et al. [30]        | Germany   | 60                         | 80% (PD)           | Not mentioned         | Single-blinded   | Computer-generated     | No                                            |
| Christodoulides et al. [12]| Germany | 24 (13/11)                | 80% (PD)           | Not mentioned         | Not given        | Coin toss              | Yes                                           |
| Braun et al. [11]         | Germany   | 20 (9/11)                 | Not mentioned      | Not mentioned         | Single-blinded   | Not mentioned          | Yes                                           |
| Chondros et al. [13]      | Germany   | 24 (10/14)                | 80% (PD)           | Not mentioned         | Single-blinded   | Coin toss              | Yes                                           |

3.5. Smokers

Smoking has been associated with an increased occurrence of periodontitis. Table 1 shows that four of the 19 studies included both smokers and non-smokers [13,27–29]. Of these, two showed an improved reduction in PD compared with a control group [27,29]. When interpreting the results, it should be noted that an intention-to-treat analysis was not mentioned in a few studies. Studies by Cappuyns et al. [29] and Chondros et al. [13] included smokers and showed microbiological improvement, while immunological profiles were found to be improved in the study by Campanile et al. [27]. In this study, although detection frequencies of periodontal pathogens did not change significantly from baseline to month 3 or 6 in any group, significant overall decreases were observed from baseline to month 6 for C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin. Single or double episodes of aPDT showed some additional benefit over ultrasonic instrumentation alone.

3.6. Photosensitizing Agents and Wavelengths Used in aPDT

Antimicrobial photodynamic therapy has been applied using various combinations of lasers and photosensitizing (PS) agents. Methylene blue (3,7-bis(dimethyl-amino) phenazathionium chloride tetramethylthionine chloride) was the most commonly used photosensitizing dye in the clinical trials. Toluidine blue O was also reported [24,25,30]. Table 3 shows the laser settings of the included studies. Toluidine blue O and methylene blue have similar chemical and physicochemical characteristics and have been used previously to detect mucosal tumors or atypical epithelia because they do not stain normal mucosa. They are the PS agents of choice for aPDT because they have a pronounced cationic charge that helps them bind to the outer membrane of Gram-negative bacteria and penetrate bacterial cells, thereby demonstrating a high degree of selectivity for killing microorganisms compared with host mammalian cells [37,38]. These dyes have been used in various concentrations (1 mg/mL to 10 mg/mL) with a residence time of 1 to 5 min in the periodontal pocket. Only two studies reported the quantity of PS used, which was either 0.2 mL methylene blue or 1 mL [25,27]. After a resident period of 1 to 3 min, excess PS was flushed off so that it would not act as an optical shield during laser irradiation [23].
Diode lasers between the wavelength of 635 nm and 670 nm were commonly used, although wavelengths of 808 nm [20] and 940 nm [22] were used in some studies. Optical fiber applicators with various diameters, ranging from 200 µm to 750 µm, were used. The laser application time was generally 60 s, although application times of 30 s [22] and 150 s [25] were also reported. Laser energy between 3 J/cm² and 320 J/cm² was used. The large differences in these laser parameters make it impossible to compare the results reported by various studies.

Table 3. Laser parameters of the included studies.

| Author Country | Photosensitizer Concentration | Resident Time of Photosensitizer | Laser Application Time | Laser Wavelength | Laser Output Energy | Fiber Optic Tip Diameter | Laser Energy |
|----------------|-------------------------------|----------------------------------|------------------------|------------------|---------------------|--------------------------|--------------|
| Kolbe et al. [26] Brazil | Methylene blue 10 mg/mL | 1 min | 1 min | 660 nm | 60 mw/cm² | Not mentioned | 129 J |
| Carvalho et al. [33] Brazil | Methylene blue 0.01% | 5 min | 1 min | 660 nm | 40 mw/cm² | Not mentioned | 90 J |
| Betsy et al. [22] India | Methylene blue 10 mg/mL | 3 min | 1 min | 655 nm | 1 W/cm² | 200 µm | Not mentioned |
| Luchesi et al. [19] Brazil | Methylene blue 10 mg/mL | 1 min | 1 min | 660 nm | 60 mw/cm² | 600 µm | 129 J |
| Diluz et al. [20] Turkey | Methylene blue 25 g | 3 min | 1 min | 808 nm | 100 mw/cm² | 300 µm | 6 J |
| Alwaeli et al. [32] Malaysia | Phenothiazine chloride | 1 min | 1 min | 660 nm | 100 mw/cm² | Not mentioned | Not mentioned |
| Campanile et al. [27] Switzerland | Methylene blue | 1 min | 1 min | 670 nm | 280 mw/cm² | Not mentioned | Not mentioned |
| Balata et al. [18] Brazil | Methylene blue 0.01% | 2 min | 1 min | 660 nm | 100 mw/cm² | Not mentioned | 320 J |
| Bassi et al. [24] USA | Toluidine blue O 0.1 mg/mL | 3 min | 1 min | 635 nm | 2 W/cm² | Not mentioned | Not mentioned |
| Backerd et al. [21] Germany | Methylene blue 0.01% | 2 min | 1 min | 670 nm | 150 mw/cm² | 600 µm | Not mentioned |
| Giannelli et al. [39] Italy | Phenothiazine 0.03% | 5 min | 1 min | 643 nm | 100 mw/cm² | 600 µm | 3.8 J |
| Giampopoulos et al. [28] Switzerland | Phenothiazine chloride, 100 µg/mL | 3 min | 1 min | 660 nm | 100 mw/cm² | 750 µm | 7 J |
| Bassi et al. [24] USA | Toluidine blue O 0.1 mg/mL | 3 min | 1 min | 635 nm | 2 W/cm² | Not mentioned | Not mentioned |
| Theodore et al. [25] Brazil | Toluidine blue O 100 µg/mL | 1 min | 30 s | 660 nm | 400 mw/cm² | Not mentioned | Not mentioned |
| Sigush et al. [31] Germany | Phenothiazine | 1 min | 1 min | 660 nm | 60 mw/cm² | 0.6 mm | Not mentioned |
| Rahing et al. [36] Germany | Toluidine chloride 5% | Not mentioned | 1 min | 635 nm | 100 mw/cm² | Not mentioned | Not mentioned |
| Chaisiddhulde et al. [12] Germany | Phenothiazine | 3 min | 1 min | 670 nm | 75 mw/cm² | Not mentioned | Not mentioned |
| Braun et al. [11] Germany | Phenothiazine | 3 min | 1 min | 660 nm | 100 mw/cm² | Not mentioned | Not mentioned |
| Chondros et al. [13] Germany | Phenothiazine | Not mentioned | 1 min | 670 nm | 75 mw/cm² | Not mentioned | Not mentioned |

Wavelength and energy density are both important factors in the efficacy of lasers, and wavelength and optimal dose with an appropriate photosensitizer are practical variables in the bactericidal process [40]. It appears that differences in these factors led to different results.

3.7. Frequency of aPDT Application

Most of the studies included used a single session of aPDT, but some [22,24,27] used multiple applications (Table 3). The results of these studies on the effects of aPDT in terms of pocket depth reduction and clinical attachment gain differ. Two of the three studies that applied aPDT more than once showed improvements in clinical parameters compared to the control group [22,27]. These two studies also showed improvements in both immunological and microbiological parameters, which could be related to the repeated use of aPDT. De Paula Eduardo et al. [41] found that the application of multiple laser treatments is more effective than a single treatment. Multiple uses of aPDT during the
first weeks of treatment may have increased the antimicrobial effect. One study [42] mentioned that the short time of exposure to light can be one reason for aPDT’s lack of effect.

3.8. Effect of aPDT on Clinical Parameters

Primary outcome measures were probing pocket depth reduction and CAL gain, which were defined as the difference between PD and CAL levels, respectively, at baseline and at the end of the follow-up period [33,43]. A change in bleeding on probing was the most common secondary outcome among the clinical parameters [44]. Microbiologic and immunologic changes, any adverse effect reported by the authors, and patient-based outcome measures were also studied [45]. All studies included in this review evaluated the effect of aPDT on clinical parameters (Table 2). Changes in PD and CAL were reported in all studies. While nine studies [11,21–23,27,31–34] reported improvements in PD following aPDT, the remaining studies did not report any additional benefit of aPDT compared to SRP [12,13,18–20,24–26,28–30]. These outcome parameters were re-evaluated at various time intervals, ranging from two weeks to one year. The results must be interpreted carefully as various factors could affect the results of aPDT. Pressure-calibrated probes [11] and examiner calibrations [12,13,18–20,23–26,32] were used in several studies for standardization.

3.9. Antimicrobial Effect of aPDT in Chronic Periodontitis

Pathogenic periodontal microorganisms such as Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Parvimonas micra have been destroyed by photodynamic action [46]. The reduction of the biological activities of the key virulence factors, such as lipopolysaccharide and proteases, may act as an additional benefit. In comparison, microbiological changes were not well evaluated, as shown in Table 4. Only eight of the 20 studies reported microbiological changes. Six of these [13,19,25,29,31,33] reported a reduction in periodontal pathogens in the test group at various time intervals. Clinical improvements along with microbiological changes were observed in two studies [29,31]. PCR was used in all studies but one to detect the microbiological changes; in that study, RNA probes were used [29]. Sigusch et al. [31] studied Fusobacterium nucleatum-infected chronic periodontitis patients. Other organisms that were evaluated included Eubacterium nodatum [13], Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Treponema denticola, Prevotella intermedia, Parvimonas micra, Fusobacterium nucleatum, Eikenellacorrodens, and Capnocytophaga sp. [19,25,29]. Significant reductions were observed in the levels of F. nucleatum [13,31], E. nodatum [13], P. gingivalis, T. forsythia, T. denticola [29], and E. corrodens [25]. The mechanism through which aPDT kills microorganisms such as P. gingivalis and F. nucleatum has been established [47]. The lethal photosensitization of these microorganisms must involve changes in membranes and/or plasma membrane proteins and DNA damage mediated by singlet oxygen [47].

| Author Country          | Sample Size | Outcome Measured                  | Conclusions                                                                                     |
|-------------------------|-------------|-----------------------------------|-------------------------------------------------------------------------------------------------|
| Kolbe et al. [26] Brazil | 22          | Microbiology(PCR); Pain perception (VAS) | Similar improvements noticed in clinical parameters with all treatments. PDT protocol presented inferior frequency of P. gingivalis at three months when compared with the other therapies. aPDT as an exclusive therapy may be considered a non-invasive alternative for treating residual pockets, offering advantages in the modulation of cytokines. |
| Carvalho et al. [33] Brazil | 34          | Microbiology(PCR); Pocket probing depth (PPD); CAL, BoP and PI | All treatments resulted in significant clinical improvement in patients with residual periodontal pockets. PDT failed to show superior clinical results and pathogen load reduction in persistent pockets, compared to supragingival plaque control. |
| Betsy et al. [23] India | 90          | Halitosis as perceived by patient  | Changes in PD after three months and halitosis after one month. Gingival index and gingival bleeding index improved significantly in the test group after two weeks and one month of aPDT. As an adjunct to SRP, aPDT shows effectiveness in the short term for managing chronic periodontitis. |
Table 4. Cont.

| Author Country | Sample Size | Outcome Measured | Conclusions |
|----------------|-------------|------------------|-------------|
| Luchesi et al. [19] Brazil | 37 | Microbiology (PCR); Immunology (GM-CSF, IFN-c, IL-6 and IL-8 levels) | Clinical parameters improved after both therapies. At six months, real-time PCR evaluation showed a decrease in F. gingivalis and Tanneraella forsythia only in the PDT group, with no inter-group differences. IL-4 and IL-10 levels increased in both groups at six months. GM-CSF; IL-8, IL-1β and IL-6 levels decreased only in the PDT group after three months. At three months, inter-group analyses showed that GM-CSF, IFN-c, IL-6 and IL-8 levels were lower in the PDT group. At six months, lower IL-1β levels were also observed in the PDT group. Did not promote clinical benefits for class II furcations. |
| Campanile et al. [27] Switzerland | 27 | Microbiology (PCR); Pain perception (VAS); Immunology (C-reactive protein, Serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin) | Detection frequencies of the studied microorganisms at >1000 and >100,000 cells/mL did not change significantly from baseline to month 3 or 6 in any group. Significant PD and BoP reduction after three months when aPDT given twice a week. C-reactive protein was significantly lower only if the laser had been activated twice. |
| Cappuyns et al. [29] Switzerland | 32 | Microbiology (RNA probes); Pain perception (VAS) | Statistically significant PD and BoP reduction was seen at six months. Frequencies of three microorganisms were significantly lower in aPDT- and SRP-treated than in diode soft laser-treated quadrants after 14 days, but not at months 2 and 6. aPDT resulted in fewer residual pockets after six months. |
| Giannopoulou et al. [28] Switzerland | 32 | Immunology (IL-17, basic fibroblast growth factor, granulocyte colony-stimulating factor, and macrophage inflammatory protein 1-a) | No significant differences were observed among the three treatment modalities at any time point for any biochemical parameter or enhanced expression of inflammatory mediators. |
| Theodoro et al. [25] Brazil | 33 | Microbiology (PCR) | All treatment groups showed an improvement in all clinical parameters, and a significant reduction in the proportion of sites positive for periodontopathogens at 60, 90, and 180 d compared to the baseline. None of the periodontal parameters showed a significant difference among the groups. At 180 days, PDT treatment led to a significant reduction in the percentage of sites positive for all bacteria compared to SRP alone. |
| Lui et al. [22] Hong Kong | 24 | Immunology (IL-1b levels in gingival crevicular fluid) | A significant decrease in gingival crevicular fluid volume was observed in both groups at one week, with a further decrease at one month in the test sites. The test sites showed a greater reduction of IL-1β levels in gingival crevicular fluid at one week than the control sites. No significant differences in periodontal parameters were found between the test and control teeth at three months. |
| Sigush et al. [31] Germany | 24 | Microbiology (PCR) | BoP, mean PD, and mean CAL showed improvement in the test group as compared to controls. aPDT may be used to manage periodontal inflammation and infection with F. nucleatum. |
| Chondros et al. [13] Germany | 24 | Microbiology (PCR) | Application of a single episode of aPDT to SRP failed to result in an additional improvement. Significantly higher reduction of bleeding scores in test group. At three and six months, a statistically significantly higher improvement of BoP was found in the test group. At three months after therapy, the microbiological analysis showed a statistically significant reduction of F. nucleatum and E. nodatum in the test group. |

3.10. Effect of Immunological Parameters Following aPDT

Five studies reported improvements in immunological parameters [19,22,26–28], as shown in Table 4. Improvements in levels of Interleukin (IL)-1β and IL-6, IL-4 [22], C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, α-2 macroglobulin [27], granulocyte macrophage colony-stimulating factor (GM-CSF), interferon, IL-8 [19] were reported. Among these, only one study also showed clinical improvement [27]. It should be noted that in this study, aPDT was administered twice a week. A significant overall decrease was observed from baseline to month 6 for C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin. When looking at the groups separately, C-reactive protein was significantly lower only when the laser had been activated twice. Other differences between groups were not significant.
3.11. Patient-Based Outcome Measures Reported in the Studies

Traditional measures of health outcomes do not capture patients’ perspectives of the disease, and therefore, patient-based outcomes were identified as a research priority [48]. Table 3 shows that only four studies reported patients’ perspectives of aPDT. Three of these studies [26,27,29] report pain perceptions of patients during the procedure using the visual analogue scale (VAS). In the study by Kolbe et al. [26] there were no differences in VAS scores between protocols for any of the parameters described. SRP-treated sites required significantly more anesthesia than did those treated with other therapies. Cappuyns et al. [29] reported that scores > 40 mm were similar in all treatment groups, and the tendency for more frequent VAS scores > 30 mm after SRP did not reach statistical significance. The total treatment time per quadrant, the use of local anesthetics, and the sequence of the treatments had no significant impact. Campanile et al. [27] reported patient discomfort following aPDT in periodontitis. It was found that only two of 27 patients being treated for residual periodontal pockets reported pain > 40 mm on a 0–100 mm VAS scale. Neither case was directly related to the aPDT procedure. One was due to tabmechanical debridement and another to a feeling of illumination in the eye when a pocket mesial of a first maxillary molar was irradiated. Halitosis as perceived by patients following the treatment was reported in one study [23]. Halitosis as detected by the hand-over-mouth technique was found to be improved after one month of treatment and did not persist beyond that time. There is increasing evidence that this treatment modality enhances wound healing following mechanical debridement by decontamination and tissue stimulation [49]. The latest studies have also shown that a combination of SRP and PDT results in substantially higher short-term clinical improvements, evidenced by probing depth or bleeding on probing reductions compared with SRP alone [49], including short-term reduction in A. actinomycetemcomitans levels in treating residual pockets after 3 months [46].

4. Conclusions

aPDT is emerging as a beneficial therapeutic option in the treatment of periodontitis. The results of many studies, if not all, indicate that aPDT along with SRP has a clear-cut advantage in the treatment of periodontitis. The additional benefits of aPDT in terms of clinical, microbiological, immunological, and patient-based outcomes are definitely encouraging and, hence, should be included in the routine treatment protocol of patients with periodontitis. Although there was a wide range of heterogeneity in the included studies, they all indicated that aPDT has the potential to be an effective adjunct in the treatment of chronic periodontitis. Long-term, multicenter studies with larger sample sizes are needed before aPDT can be recommended as an effect treatment modality.

Author Contributions: Betsy Joseph, Prasanthila Janam and Subhash Narayanan conceived and designed the experiments; Betsy Joseph performed the experiments; Betsy Joseph and Sukumaran Anil analyzed the data; Betsy Joseph and Sukumaran Anil wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Adriaens, P.A.; Adriaens, L.M. Effects of nonsurgical periodontal therapy on hard and soft tissues. Periodontology 2000 2004, 36, 121–145. [CrossRef] [PubMed]
2. Umeda, M.; Takeuchi, Y.; Noguchi, K.; Huang, Y.; Koshy, G.; Ishikawa, I. Effects of nonsurgical periodontal therapy on the microbiota. Periodontology 2000 2004, 36, 98–120. [CrossRef] [PubMed]
3. Hanes, P.J.; Purvis, J.P. Local anti-infective therapy: Pharmacological agents. A systematic review. Ann. Periodontol. 2003, 8, 79–98. [CrossRef] [PubMed]
4. Assem, N.Z.; Alves, M.L.F.; Lopes, A.B.; Gualberto, E.C.J.; Garcia, V.G.; Theodoro, L.H. Antibiotic therapy as an adjunct to scaling and root planing in smokers: A systematic review and meta-analysis. Braz. Oral Res. 2017, 31, e67. [CrossRef] [PubMed]
5. Dobson, J.; Wilson, M. Sensitization of oral bacteria in biofilms to killing by light from a low-power laser. *Arch. Oral Biol.* 1992, 37, 883–887. [CrossRef]

6. Komerik, N.; Nakanishi, H.; MacRobert, A.J.; Henderson, B.; Speight, P.; Wilson, M. In vivo killing of *porphyromonas gingivalis* by toluidine blue-mediated photosensitization in an animal model. *Antimicrob. Agents Chemother.* 2003, 47, 932–940. [CrossRef] [PubMed]

7. Williams, J.A.; Pearson, G.J.; Collies, M.J.; Wilson, M. The photo-activated antibacterial action of toluidine blue o in a collagen matrix and in carious dentine. *Caries Res.* 2004, 38, 530–536. [CrossRef] [PubMed]

8. Williams, J.A.; Pearson, G.J.; Collies, M.J.; Wilson, M. The effect of variable energy input from a novel light source on the photoactivated bactericidal action of toluidine blue o on *streptococcus mutans*. *Caries Res.* 2003, 37, 190–193. [CrossRef] [PubMed]

9. Wilson, M.; Burns, T.; Pratten, J.; Pearson, G.J. Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer. *J. Appl. Bacteriol.* 1995, 78, 569–574. [CrossRef] [PubMed]

10. Azarpazhooh, A.; Shah, P.S.; Tenenbaum, H.C.; Goldberg, M.B. The effect of photodynamic therapy for periodontitis: A systematic review and meta-analysis. *J. Periodontol.* 2010, 81, 4–14. [CrossRef] [PubMed]

11. Braun, A.; Dehn, C.; Krause, F.; Jepsen, S. Short-term clinical effects of adjunctive antimicrobial photodynamic therapy in periodontal treatment: A randomized clinical trial. *J. Clin. Periodontol.* 2008, 35, 877–884. [CrossRef] [PubMed]

12. Christodoulides, N.; Nikolidakis, D.; Chondros, P.; Becker, J.; Schwarz, F.; Rossler, R.; Sculean, A. Photodynamic therapy as an adjunct to non-surgical periodontal treatment: A randomized, controlled clinical trial. *J. Periodontol.* 2008, 79, 1638–1644. [CrossRef] [PubMed]

13. Chondros, P.; Nikolidakis, D.; Christodoulides, N.; Rossler, R.; Gutknecht, N.; Sculean, A. Photodynamic therapy as adjunct to non-surgical periodontal treatment in patients on periodontal maintenance: A randomized controlled clinical trial. *Lasers Med. Sci.* 2009, 24, 681–688. [CrossRef] [PubMed]

14. Lulic, M.; Leiggener Gorog, I.; Salvi, G.E.; Ramseier, C.A.; Mattheos, N.; Lang, N.P. One-year outcomes of repeated adjunctive photodynamic therapy during periodontal maintenance: A proof-of-principle randomized-controlled clinical trial. *J. Clin. Periodontol.* 2009, 36, 661–666. [CrossRef] [PubMed]

15. Atieh, M.A. Photodynamic therapy as an adjunctive treatment for chronic periodontitis: A meta-analysis. *Lasers Med. Sci.* 2010, 25, 605–613. [CrossRef] [PubMed]

16. Sgolastra, F.; Petrucci, A.; Gatto, R.; Marzo, G.; Monaco, A. Photodynamic therapy in the treatment of chronic periodontitis: A systematic review and meta-analysis. *Lasers Med. Sci.* 2013, 28, 669–682. [CrossRef] [PubMed]

17. Miller, S.A.; Forrest, J.L. Enhancing your practice through evidence-based decision making: Pico, learning how to ask good questions. *J. Evid. Based Dent. Pract.* 2001, 1, 136–141. [CrossRef]

18. Balata, M.L.; Andrade, L.P.; Santos, D.B.; Cavalcanti, A.N.; Tunes Uda, R.; Ribeiro Edel, P.; Bittencourt, S. Photodynamic therapy associated with full-mouth ultrasonic debridement in the treatment of severe chronic periodontitis: A randomized-controlled clinical trial. *J. Appl. Oral Sci.* 2013, 21, 208–214. [CrossRef] [PubMed]

19. Luchesi, V.H.; Pimentel, S.P.; Kolbe, M.F.; Ribeiro, F.V.; Casarin, R.C.; Nociti, F.H., Jr.; Sallum, E.A.; Casati, M.Z. Photodynamic therapy in the treatment of class ii furcation: A randomized controlled clinical trial. *J. Clin. Periodontol.* 2013, 40, 781–788. [CrossRef] [PubMed]

20. Dilsiz, A.; Canakci, V.; Aydin, T. Clinical effects of potassium-titanyl-phosphate laser and photodynamic therapy on outcomes of treatment of chronic periodontitis: A randomized controlled clinical trial. *J. Periodontol.* 2013, 84, 278–286. [CrossRef] [PubMed]

21. Berakdar, M.; Callaway, A.; Eddin, M.F.; Ross, A.; Willershausen, B. Comparison between scaling-root-planing (srp) and srp/photodynamic therapy: Six-month study. *Head Face Med.* 2012, 8, 12. [CrossRef] [PubMed]

22. Lui, J.; Corbet, E.F.; Jin, L. Combined photodynamic and low-level laser therapies as an adjunct to nonsurgical treatment of chronic periodontitis. *J. Periodontal. Res.* 2011, 46, 89–96. [CrossRef] [PubMed]

23. Betsy, J.; Prasanth, C.S.; Baiju, K.V.; Prasanthila, J.; Subhash, N. Efficacy of antimicrobial photodynamic therapy in the management of chronic periodontitis: A randomized controlled clinical trial. *J. Clin. Periodontol.* 2014, 41, 573–581. [CrossRef] [PubMed]
24. Bassir, S.H.; Moslemi, N.; Jamali, R.; Mashmouly, S.; Fekrazad, R.; Chiniforush, N.; Shamshiri, A.R.; Nowzari, H. Photoactivated disinfection using light-emitting diode as an adjunct in the management of chronic periodontitis: A pilot double-blind split-mouth randomized clinical trial. *J. Clin. Periodontol.* 2013, 40, 65–72. [CrossRef] [PubMed]

25. Theodoro, L.H.; Silva, S.P.; Pires, J.R.; Soares, G.H.; Pontes, A.E.; Zuza, E.P.; Spolidorio, D.M.; de Toledo, B.E.; Garcia, V.G. Clinical and microbiological effects of photodynamic therapy associated with nonsurgical periodontal treatment. A 6-month follow-up. *Lasers Med. Sci.* 2012, 27, 687–693. [CrossRef] [PubMed]

26. Kolbe, M.F.; Ribeiro, F.V.; Luchesi, V.H.; Casarin, R.C.; Sallum, E.A.; Nociti, F.H., Jr.; Ambrosano, G.M.; Cirano, F.R.; Pimentel, S.P.; Casati, M.Z. Photodynamic therapy during supportive periodontal care: Clinical, microbiologic, immunoinflammatory, and patient-centered performance in a split-mouth randomized clinical trial. *J. Periodontol.* 2014, 85, e277–e286. [CrossRef] [PubMed]

27. Campanile, V.S.M.; Giannopoulou, C.; Campanile, G.; Cancela, J.A.; Mombelli, A. Single or repeated antimicrobial photodynamic therapy as adjunct to ultrasonic debridement in residual periodontal pockets: Clinical, microbiological, and local biological effects. *Lasers Med. Sci.* 2013, 30, 27–34. [CrossRef] [PubMed]

28. Giannopoulou, C.; Cappuyns, I.; Cancela, J.; Cionca, N.; Mombelli, A. Effect of photodynamic therapy, diode laser, and deep scaling on cytokine and acute-phase protein levels in gingival crevicular fluid of residual periodontal pockets. *J. Periodontal.* 2012, 83, 1018–1027. [CrossRef] [PubMed]

29. Cappuyns, I.; Cionca, N.; Wick, P.; Giannopoulou, C.; Mombelli, A. Treatment of residual pockets with photodynamic therapy, diode laser, or deep scaling. A randomized, split-mouth controlled clinical trial. *Lasers Med. Sci.* 2012, 27, 979–986. [CrossRef] [PubMed]

30. Ruhling, A.; Fanghanel, J.; Houshmand, M.; Kuh, A.; Meisel, P.; Schwahn, C.; Kocher, T. Photodynamic therapy of persistent pockets in maintenance patients—a clinical study. *Clin. Oral Investig.* 2010, 14, 637–644. [CrossRef] [PubMed]

31. Sigusch, B.W.; Engelbrecht, M.; Volpel, A.; Holletschke, A.; Pfister, W.; Schutze, J. Full-mouth antimicrobial photodynamic therapy in *fusobacterium nucleatum*-infected periodontitis patients. *J. Periodontol.* 2010, 81, 975–981. [CrossRef] [PubMed]

32. Alwaeli, H.A.; Al-Khateeb, S.N.; Al-Sadi, A. Long-term clinical effect of adjunctive antimicrobial photodyanmic therapy in periodontal treatment: A randomized clinical trial. *Lasers Med. Sci.* 2015, 30, 801–807. [CrossRef] [PubMed]

33. Carvalho, V.F.; Andrade, P.V.; Rodrigues, M.F.; Hirata, M.H.; Hirata, R.D.; Pannuti, C.M.; De Micheli, G.; Conde, M.C. Antimicrobial photodynamic effect to treat residual pockets in periodontal patients: A randomized controlled clinical trial. *J. Clin. Periodontol.* 2015, 42, 440–447. [CrossRef] [PubMed]

34. Campos, G.N.; Pimentel, S.P.; Ribeiro, F.V.; Casarin, R.C.; Cirano, F.R.; Saraceni, C.H.; Casati, M.Z. The adjunctive effect of photodynamic therapy for residual pockets in single-rooted teeth: A randomized controlled clinical trial. *Lasers Med. Sci.* 2013, 28, 317–324. [CrossRef] [PubMed]

35. Smail-Faugeron, V.; Fron-Chabouis, H.; Courson, F.; Durieux, P. Comparison of intervention effects in split-mouth and parallel-arm randomized controlled trials: A meta-epidemiological study. *BMC Med. Res. Methodol.* 2014, 14, 64. [CrossRef] [PubMed]

36. Donner, A.; Eliaziw, M. Application of matched pair procedures to site-specific data in periodontal research. *J. Clin. Periodontol.* 1991, 18, 755–759. [CrossRef] [PubMed]

37. Gomer, C.J. Preclinical examination of first and second generation fotosensitizers used in photodynamic therapy. *Photochem. Photobiol.* 1991, 54, 1093–1107. [CrossRef] [PubMed]

38. Olsen, C.E.; Weyergang, A.; Edwards, V.T.; Berg, K.; Brech, A.; Weisheit, S.; Hogset, A.; Selbo, P.K. Development of resistance to photodynamic therapy (pdt) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming pdt-resistance. *Biochem. Pharmacol.* 2017, 144, 63–77. [CrossRef] [PubMed]

39. Giannelli, M.; Formigli, L.; Lorenzini, L.; Bani, D. Combined photoablative and photodynamic diode laser therapy as an adjunct to non-surgical periodontal treatment: A randomized split-mouth clinical trial. *J. Clin. Periodontol.* 2012, 39, 962–970. [CrossRef] [PubMed]

40. Chan, Y.; Lai, C.H. Bactericidal effects of different laser wavelengths on periodontopathic germs in photodynamic therapy. *Lasers Med. Sci.* 2003, 18, 51–55. [CrossRef] [PubMed]
41. de Paula Eduardo, C.; de Freitas, P.M.; Esteves-Oliveira, M.; Aranha, A.C.; Ramalho, K.M.; Simoes, A.; Bello-Silva, M.S.; Tuner, J. Laser phototherapy in the treatment of periodontal disease. A review. *Lasers Med. Sci.* **2010**, *25*, 781–792. [CrossRef] [PubMed]

42. Soukos, N.S.; Goodson, J.M. Photodynamic therapy in the control of oral biofilms. *Periodontology 2000* **2011**, *55*, 143–166. [CrossRef] [PubMed]

43. Bunaes, D.F.; Lie, S.A.; Enersen, M.; Aastrom, A.N.; Mustafa, K.; Leknes, K.N. Site-specific treatment outcome in smokers following non-surgical and surgical periodontal therapy. *J. Clin. Periodontol.* **2015**, *42*, 933–942. [CrossRef] [PubMed]

44. Garcia Canas, P.; Khouly, I.; Sanz, J.; Loomer, P.M. Effectiveness of systemic antimicrobial therapy in combination with scaling and root planing in the treatment of periodontitis: A systematic review. *J. Am. Dent. Assoc.* **2015**, *146*, 150–163. [CrossRef] [PubMed]

45. Preus, H.R.; Dahlen, G.; Gjermo, P.; Baelum, V. Microbiologic observations after four treatment strategies among patients with periodontitis maintaining a high standard of oral hygiene: Secondary analysis of a randomized controlled clinical trial. *J. Periodontol.* **2015**, *86*, 856–865. [CrossRef] [PubMed]

46. Correa, M.G.; Oliveira, D.H.; Saraceni, C.H.; Ribeiro, F.V.; Pimentel, S.P.; Cirano, F.R.; Casarin, R.C. Short-term microbiological effects of photodynamic therapy in non-surgical periodontal treatment of residual pockets: A split-mouth rct. *Lasers Surg. Med.* **2016**, *48*, 944–950. [CrossRef] [PubMed]

47. Maisch, T. Anti-microbial photodynamic therapy: Useful in the future? *Lasers Med. Sci.* **2007**, *22*, 83–91. [CrossRef] [PubMed]

48. Tonetti, M.S.; Fourmousis, I.; Suvan, J.; Cortellini, P.; Bragger, U.; Lang, N.P.; European Research Group on Periodontology (ERGOPERIO). Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects. *J. Clin. Periodontol.* **2004**, *31*, 1092–1098. [CrossRef] [PubMed]

49. Sculean, A.; Aoki, A.; Romanos, G.; Schwarz, F.; Miron, R.J.; Cosgarea, R. Is photodynamic therapy an effective treatment for periodontal and peri-implant infections? *Dent. Clin. N. Am.* **2015**, *59*, 831–858. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).